Last reviewed · How we verify
Dabigatranetexilate
Dabigatranetexilate is a Small molecule drug developed by University of Ulm. It is currently FDA-approved. Also known as: Pradaxa.
At a glance
| Generic name | Dabigatranetexilate |
|---|---|
| Also known as | Pradaxa |
| Sponsor | University of Ulm |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabigatranetexilate CI brief — competitive landscape report
- Dabigatranetexilate updates RSS · CI watch RSS
- University of Ulm portfolio CI
Frequently asked questions about Dabigatranetexilate
What is Dabigatranetexilate?
Dabigatranetexilate is a Small molecule drug developed by University of Ulm.
Who makes Dabigatranetexilate?
Dabigatranetexilate is developed and marketed by University of Ulm (see full University of Ulm pipeline at /company/university-of-ulm).
Is Dabigatranetexilate also known as anything else?
Dabigatranetexilate is also known as Pradaxa.
What development phase is Dabigatranetexilate in?
Dabigatranetexilate is FDA-approved (marketed).
Related
- Manufacturer: University of Ulm — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Pradaxa
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing